US FDA Grants Mexiletine Orphan Drug Designation
US FDA Grants Mexiletine Orphan Drug Designation Zug, Switzerland, 8 June 2019: Lupin is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to mexiletine hydrochloride for the treatment of myotonic …